RxSight announced it has surpassed 300,000 implants of its Light Adjustable Lens (LAL), a unique intraocular lens technology allowing post-surgery vision customization. This milestone highlights the growing adoption and clinical success of LAL, supported by 35 scientific presentations at the ASCRS 2026 meeting. The company also launched a new program featuring ophthalmologists who personally trust the LAL technology. RxSight continues expanding its network of trained surgeons to make personalized cataract surgery widely accessible.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Ecopetrol, Colombia's largest energy company, will announce its financial and operating results for the second quarter of 2026 on August 3 after market close. A virtual conference will follow on August 4, featuring simultaneous Spanish and English br...
Galaxy Digital reports that large Bitcoin holders (whales) have not sold their holdings over fears of quantum computing risks. Instead, concerns about quantum threats seem to influence institutional investors who are hesitant to buy Bitcoin. Recent l...
Visionstate Corp. has decided to pause its previously announced non-brokered private placement financing under the LIFE exemption, initially targeting $500,000 to $1,000,000. The company will use this time to reconsider the structure and timing of th...
